Combining immunotherapy with chemotherapy as an upfront treatment is of interest at this point for all small cell carcinomas as chemotherapy showed the potential to increase the PD-L1 expression within the tumor microenvironment, which will enhance the responses to PD-1 inhibitors [23–25]. The gene discussed is CD274; the disease is neoplasm.